PhaseRx Cultura da Companhia

Dr. Paul H. Johnson, PhD Co-Founded PhaseRx Inc. in November 2007 and served as its Chief Scientific Officer. Dr. Johnson served as Senior Vice President of Research & Development and Chief Scientific Officer of Nastech Pharmaceutical Co Inc. from September 2003 to October 6, 2007. Prior to that, Dr. Johnson served as Vice President, Research and Development And Chief Scientific Officer at EpiGenX Pharmaceuticals, Inc. from 2001 to 2003. Before that Dr. Johnson served as the Head of the Cell and Molecular Biology Department and Principal Scientist in the Cancer Research Department at Berlex Biosciences in Richmond, California, the U.S. Research and Development Center for Schering AG in Germany from 1994 to 2001 and also held an adjunct faculty position in the Graduate Division of Molecular Biology and Biochemistry at the University of California at Davis. He has been a Director of PhaseRx Inc since November 2007. He served as Director of the Cell and Molecular Biology Laboratory at SRI International (formerly the Stanford Research Institute) and Professor of Biochemistry at Wayne State University Medical School from 1975 to 1994. In his professional career he has led the implementation of innovative approaches for the discovery, validation and development of novel therapeutics and associated genomics-based diagnostic technologies. He has also established processes for commercial development and transfer of product candidates to partnerships; planned and managed research and development activities; built a scientific staff focused on key internal research and development activities; implemented new technologies for pharmaceutical discovery and development and established/acquired intellectual property rights; developed and managed external collaborations; contributed to the development of strategic business and marketing plans; and served as the scientific spokesman for Nastech Pharmaceutical Co Inc. in its corporate development initiatives. Dr. Johnson is an author on numerous scientific papers and abstracts and patents. He is a recipient of the 2007 Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery. Dr. Johnson received a B.S. in Biological Sciences from the State University of New York, Buffalo and a Ph.D. in Biochemistry from the Roswell Park Cancer Institute (SUNY), and completed his Post-Doctoral Training at the California Institute of Technology under an American Cancer Society fellowship.

Dr. Patrick Stayton, also known as Pat, Ph.D. co-founded PhaseRx, Inc. in 2006. Dr. Stayton is a Professor of Department of Bioengineering at University of Washington. He serves as a Member of Science Advisory Board at Stratos Genomics Inc. He served as a Member of Scientific Advisory Board of PhaseBio Pharmaceuticals, Inc. (also known as Phase Bioscience, Inc.).

Prof. Allan S. Hoffman, Ph.D., co-founded PhaseRx, Inc. in 2006. Dr. Hoffman serves as a joint Professor of Bioengineering at the University of Washington, where an endowed lectureship in Biomaterials and Molecular Bioengineering is given annually in his honor. He served as an Advisor of Biocompatibles International Plc. He serves as a Member of Scientific Advisory Board at Inson Medical Systems, Inc. He serves as a Member of Scientific Advisory Board of MacroChem Corporation. He served as a Member of the Scientific Advisory Board at Nfocus Neuromedical, Inc. He served as the President for the Society of Biomaterials and serves as the chairman for the Gordon Conference on Biomaterials. Dr. Hoffman serves as a Trustee and a Member of the board of directors at the International Society of Artificial Organs. In 2005, he was elected into the National Academy of Engineering, U.S.A., for his ???Pioneering Work on the Medical Uses of Polymeric Materials.??? Both the Controlled Release Society and the Society for Biomaterials have awarded him as a their prestigious Founder's Awards (2007 and 2000) for his lifetime of achievements in the areas of controlled release for drug delivery and 'smart??? polymers. He is the author of more than 350 scholarly works. Dr. Hoffman received his Ph.D. in Chemical Engineering in 1957.

Dr. Oliver W. Press, M.D., Ph.D. co-founded PhaseRx, Inc. in 2006. Dr. Press serves as a Member of Advisory Board of Trubion Pharmaceuticals Inc. He serves as a Member of Scientific Advisory Board of Algeta ASA. He served as a Member of Scientific Advisory Board at Converge Medical, Inc. Dr. Press is Professor in the Division of Oncology at the University of Washington. Dr. Press is known internationally for his pioneering work within immunotherapy in general and the immunotherapy of non-Hodgkin's Lymphoma in particular.